Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1

Status

Recruiting 2No longer available 1Completed 1

Sponsor Class

OTHER 9INDUSTRY 4NETWORK 3NIH 1

Study Type

Interventional 3Expanded_access 1

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 1Gastrointestinal 1

Conditions

Leukemia, Myeloid, Acute 2Leukemia 2Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Biphenotypic, Acute 1Colorectal Neoplasms 1

Interventions

pembrolizumab 604Carboplatin 372Paclitaxel 282Cisplatin 267Gemcitabine 252Pemetrexed 193Bevacizumab 190Docetaxel 185Nivolumab 181Injections 167Cyclophosphamide 147atezolizumab 138Fluorouracil 133Capecitabine 133Oxaliplatin 132Dexamethasone 127Fulvestrant 113durvalumab 112130-nm albumin-bound paclitaxel 110fludarabine 101Cetuximab 100Leucovorin 97Rituximab 94venetoclax 90Lenalidomide 83enzalutamide 77Prednisone 76Azacitidine 74Irinotecan 72Ipilimumab 72

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × revumenib × 1 year × Clear all
NCT07211958 2026-05-20

REVEAL-ND NPM1

Syndax Pharmaceuticals

Phase 3 Recruiting
468 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04065399 2026-03-18

AUGMENT-101

Syndax Pharmaceuticals

Phase 1/2 Recruiting
447 enrolled 2 FDA
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05731947 2026-01-29

Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors

Syndax Pharmaceuticals

Phase 1/2 Completed
42 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT05918913 2025-09-05

Expanded Access Program for Revumenib

Syndax Pharmaceuticals

No longer available
1 FDA
Other hematologic neoplasm

Leukemia, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡